Navigation Links
Hundreds of alterations and potential drug targets to starve cancer tumors identified
Date:4/21/2013

mote tumor formation as a result of efflux from mitochondria and accumulation of their substrates, fumarate and succinate. The researchers found that in colon cancer, accumulation of these metabolites may be caused by a significant decrease in the enzymes' expression. This was confirmed when metabolomics data from colon tumor patients showed significantly higher concentrations of fumarate in tumors than in normal tissue.

"These are just several examples of how cancer cells use various creative mechanisms to hijack the metabolism of native cells for their own purposes," said Dr. Vitkup.

For cancer researchers looking for new drug targets, Dr. Vitkup's team also found hundreds of differences between normal and cancer cells' use of isoenzymes. This opens up additional possibilities for turning off cancer's fuel and supply lines. Isoenzymes often catalyze the same reactions, but have different kinetic properties: Some act quickly and sustain rapid growth, while others are more sluggish. In kidney and liver cancers, for example, a quick-acting aldolase isoenzymesuitable for fast cell proliferationwas found to be more prevalent than the more typical slow-moving version found in normal kidney and liver tissue. Although a few examples of differential isoenzyme expression in tumors were already known, the Columbia researchers identified hundreds of isoenzymes with cancer-specific expression patterns.

"Inhibiting specific isoenzymes in tumors may be a way to selectively hit cancer cells without affecting normal cells, which could get by with other isoenzymes," said Dr. Hu.

In fact, a recent study from Matthew Vander Heiden's laboratory demonstrated the potential of targeting a specific isoenzyme, pyruvate kinase M2, expression of which often increases in tumors. "The comprehensive expression analysis suggests that a similar approach could potentially be applied in multiple other cases," said Dr. Vander Heiden.

Targeting metabolis
'/>"/>

Contact: Karin Eskenazi
ket2116@cumc.columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Hundreds of random mutations in leukemia linked to aging, not cancer
2. Physicians at Pain Care Bring Hope to Hundreds of Pain Management Patients Who Previously Had None Through Use of a New Procedure Called Spinal Cord Stimulation
3. High-throughput sequencing shows potentially hundreds of gene mutations related to autism
4. Medtronic Infuse Bone Graft Lawsuits: Bernstein Liebhard LLP Notes New Report Predicting Hundreds of Medtronic Infuse Lawsuits
5. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
6. Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers
7. Study identifies potential treatment for lethal childhood leukemia
8. McMaster researchers find potential for new uses of old drug
9. Army researcher develops potential vaccine carrier
10. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
11. New study of NIH funding allocations suggests potential efficiency gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Becker's Hospital ... "100 Hospitals and Health Systems With Great Oncology Programs." ... in terms of quality patient care, cancer outcomes and ... hospitals for inclusion based on rankings and awards they ... following awards were considered as part of the criteria ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The European Omega ... omega 3 & structured lipids market in Europe with analysis ... from around $670.37 million in 2012 to $989.91 million by ... , Browse through the TOC of the European omega 3 ... the in-depth analysis provided. This also provides a glimpse of ...
(Date:7/24/2014)... 24, 2014 The European air and missile ... 2014, and is expected to register a CAGR of 8.06%, ... Russia, and turkey are the major spenders in the region ... extended air defense program and multinational (MEADS) program, which has ... through the TOC of the Europe air and missile defense ...
(Date:7/24/2014)... p53 refers to cancer biology, and the functions of ... in detail. Furthermore, also in cancer biology, it is ... cells in order to block their metabolism and prevent ... research on p53 attempts to unveil its functions in ... cells. Recent studies with cell cultures have demonstrated that ...
(Date:7/24/2014)... malaria parasite becomes resistant to an investigational drug. ... in St. Louis, also is relevant for other ... The study appears July 24 in Nature ... that causes malaria, make a class of molecules ... organisms healthy, whether plants, animals or bacteria. In ...
Breaking Medicine News(10 mins):Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
... MEDI3) (MEDIAL SAUDE) announces the following webcast:, What: Medial Saude ... 2008 @ 12:00 PM EDT, Where: http://prnewswire.isat.com.br/?palestra_id=305 , How: ... the address above., ... Toll-free from the US: (1 800) 860-2442; ...
... might be swaying clinicians , , WEDNESDAY, May ... overdiagnosed, say researchers at Rhode Island Hospital and ... half of patients previously diagnosed with bipolar disorder ... -- the Structured Clinical Interview for DSM-IV (SCID). ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... new data analysis that was conducted to examine ... boys and girls aged 6 to 12 years ... findings from the analysis reaffirmed that DAYTRANA has ...
... Agrees to $2.3 million fine, CARMEL, Ind., ... ),today announced a settlement among state insurance regulators ... Insurance (CSHI) Company,and Bankers Life and Casualty Company. ... by Pennsylvania, Illinois,Indiana, Texas and Florida related to ...
... Vail Valley ... Medical Center, VAIL, Colo., May ... today the appointment of the new President,and CEO, John H. Cassin. Cassin ... Medical Center., "John brings great leadership experience and an engaging personal,style, ...
Cached Medicine News:Health News:UAB first in US to offer speedier precise cancer radiotherapy 2Health News:Bipolar Disorder Might Be Overdiagnosed 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 3Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Vail Valley Medical Center Board of Directors Announces Appointment of New President & CEO, John Cassin 2
(Date:7/24/2014)... ANGELES , July 24, 2014  Bruin ... devices, announced today that after two weeks of ... throughout the European Union, it gained substantial concurrence ... moisture) and the clinical utility of BBI,s SEM ... over 90 percent of the respondents drawn from ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
(Date:7/24/2014)... , July 24, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... will release second quarter financial results after market close ... a webcast and conference call the same day at ... financial results and provide a corporate update. ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2
... Dec. 14, 2010 Biodel Inc. (Nasdaq: BIOD ... the company,s Chief Scientific Officer.  Dr. Steiner is a co-founder ... board of directors.  He served as Biodel,s chairman, president and ... March 2010 when Dr. Errol De Souza was named the ...
... announces that a new market research report is ... Pharmaceuticals Research Review http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html ... has accentuated the fault lines already dividing the ... pharma companies, coupled with the patent expiration precipice, ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
Karlin XL Magnum Ring Curettes, extra long (XL) curettes, black handles, lightweight. Length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Hardy Curettes, bayonet, working distance 4 3/4" (120 mm), total length 9 1/2" (241 mm), tip width 3 mm....
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Medicine Products: